You just read:

Opportunity Exists in the U.S. for Novel Agents in Crohn's Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures

News provided by

Decision Resources

Dec 10, 2013, 10:15 ET